key: cord-0813967-znb1tck8
authors: Frohman, Elliot M.; Villemarette-Pittman, Nicole; Rodriguez, Adriana; Glanzman, Robert; Rugheimer, Sarah; Komogortsev, Oleg; Zamvil, Scott S.; Cruz, Roberto Alejandro; Varkey, Thomas C.; Frohman, Ashley N.; Frohman, Audrey R.; Parsons, Matthew S.; Konkle, Emily; Frohman, Teresa C.
title: Home treatment of mild/moderate COVID-19: To prevent severe disease: IMAGINE?()
date: 2021-04-20
journal: J Neurol Sci
DOI: 10.1016/j.jns.2021.117463
sha: 3387877ef728fa9fed171c9887ebd24651841439
doc_id: 813967
cord_uid: znb1tck8

The COVID-19 pandemic has devastated individuals, families, and institutions throughout the world. Despite the breakneck speed of vaccine development, the human population remains at risk of further devastation. The decision to not become vaccinated, the protracted rollout of available vaccine, vaccine failure, mutational forms of the SARS virus, which may exhibit mounting resistance to our molecular strike at only one form of the viral family, and the rapid ability of the virus(es) to hitch a ride on our global transportation systems, means that we are will likely continue to confront an invisible, yet devastating foe. The enemy targets one of our human physiology's most important and vulnerable life-preserving body tissue; our brocho-alveolar gas exchange apparatus. Notwithstanding the fear and the fury of this microbe's potential to raise existential questions across the entire spectrum of human endeavor, the application of an early treatment intervention initiative, may represent a crucial tool in our defensive strategy. This strategy is driven by evidence-based medical practice principles, those not likely to become antiquated, given the molecular diversity and mutational evolution of this very clever “world traveler”.

Never before has the human family shared a more compelling and existential challenge, from which to acknowledge our common plight, rather than our differences.

Only through the establishment and mutual endorsement and enforcement of universal public health principles, collaborative research on a global scale, and universal preparedness to act decisively with early and strategically formulated interventions, can we hope to stay ahead of this most formidable foe [1] .

Supported by both long-established standards of care protocols, as well as randomized control trials aimed to either confirm or refute hypothesis-driven therapeutic questions on the efficacy of novel agents identified through innovations in discovery, we are on the brink of ushering in a literal Renaissance of modern medicine. The era"s overarching goal shall be to establish the most sophisticated attempt to date, utilizing discrete knowledge of human heterogeneity, for the identification of effective treatments for even a single patient; the era of Precision CARE. Until then, we share herein a protocol for the early treatment of mild and moderate COVID-19, the purpose of which is to prevent the transition to severe disease.

The circumstances of the COVID-19 crisis, created many formidably complex challenges in clinical trial design and execution. Nowhere has such complexity been

What part of us does NOT need to utilize oxygen? Insufficient oxygen delivery compromises mechanisms in our physiology which aim to match the supply of energy currency with that of tissue and organ functional demands. Most crucially, the amounts of energy currency being made (i.e. adenosine triphosphate (ATP) and its energy currency colleagues; flavin adenine dinucleotide (FAD), nicotinamide adenine dinucleotide (NAD); and all requiring oxygen to run the electron transport chain in our cellular mitochondria), become wholly inadequate to maintain the high efficiency state of the health, wellness, and quality of life that is inextricably coupled and dependent upon the integrity and high fidelity processes which characterize the biochemistry of human intermediary metabolism.

If all who are infected are urgently treated; we not only attenuate the Prolific Activation of a Network Immune Inflammatory Crisis ("PANIC") Attack of inflammation, but also abort viral replication [2] . This halt in replication also abolishes downstream tissue injury mechanisms at both ends of the COVID syndrome. These mechanisms include the parochial triggering of "PANIC", where we can least recover from the inflammatory crisis; broncho-alveolar gas exchange units of the most remote reaches of our lung anatomy and physiology. Additionally, the high-jacking of our alveolar epithelial molecular machinery for its own self-serving purposes, an additional bystander effect is the irreversible damage and obliteration of this most precious asset of gas exchange, which cannot be replaced. The prevention as well as reversing the high-jacking of our alveolar epithelial cell molecular machinery, for purposes of the SARS-CoV-2 viral replication, represents another major goal of COVID-19 treatment. Halting replication itself, reduces the inflammatory ignition switch that foments site activation of exuberant inflammation, while releasing factors (e.g. C3a and C5a; anaphylatoxins and chemotaxins) promote the redistribution of peripheral immune effector cells, recruiting them to the site of primary infection; the broncho-alveolar units. Upon the arrival of the peripheral immune effector cells to the primary site of infection, the bronco-alveolar units, the effector cells release free radicals, super oxides, and other injurious agents, all serving to intensify and expand the injury cascades.

Less viral presence also means a reduced likelihood of viral segment integration within the alveolar epithelium (as so-called "syncytia"), with SPIKE protein "dangled" into the alveolus, potentially generating antibody locally from our own B cells. This may sound like a good thing? It is not. Such locally generated antibodies against SPIKE protein on the SARS-CoV-2 virus expressed upon our alveolar epithelium, ignites the terminal complement cascade, specifically the C5-convertase. This in turn promotes the assembly of proteins derivative of the C5, C6, C7, and C8 pathway to construct the terminal and most injurious effector mechanism of the entire complement system; the membrane attack complex (MAC).

In the case of COVID-19, MAC assembly upon our alveolar epithelium is then primed for the final "kill-shot". Specifically, the MAC architecture includes a centrally serves as a direct line of sight for the bullet-like action of C9 upon reaching the terminus of the MAC, adhered to the epithelial surface. Upon its arrival, C9 then penetrates the alveolar cell membrane inflicting an irreversible breach in the integrity of the cell"s barrier, and physiologic dividing line, crucial for maintaining innumerable processes;

including those that sustain the life and viability of these cells. The "kill-shot" mechanism culminates in osmotic shock; completing what we now designate as antibody dependent-cellular-cytotoxicity (ADCC) (via complement activation). What then follows is damage commensurate with the transition to severe disease and the heightened risk of alveolar obliteration.

Now imagine if all patients were treated at the time of diagnosis, when COVID-19 is at its mildest to moderate stages, with interventions aimed at multiple mechanisms that when uncoupled, we have our best chance to protect the lung, monitor the disease process at home, and all the while being in touch with your care provider in order to provide guidance, course changes, and always with the default of hospitalization should the condition warrant closer observation and/or intensification of the treatment plans. This is a highly unusual paper. Why? Its principal purpose is to underscore the prospects and possibilities of controlling the most dangerous aspects of the COVID-19 pandemic before it begins. Imagine if the world recognized that by having the advents of public health practices, coupled with an effective home treatment regimen, while our vaccination programs come to fruition, and herd immunity is ultimately achieved. everyone) accepts the premise of the hypothesis that we put forth. We must be prepared for new variants, and to learn from the painful and cataclysmic lessons of the current pandemic. One glaring observational lesson, is that the medical community became so completely paralyzed by the increasing and inevitable onslaught of severe illness, ultimately exceeding our available resources.

One very painful outcome and lesson of this past year of the pandemic experience is that there has been almost complete lack of management of those with mild and moderate disease, as well as those wholly asymptomatic. Unfortunately, it is during this initial time, the initial assessment where patients have been summarily told to "go home and not return until you are more-sick"; which for many may represent a time when they may be beyond our capability to nurse them back to health; or even to save their lives.

This paper is our attempt to focus precisely upon strategies that have successfully "left-shifted" patients toward ultimate recovery, and away from the potential "right-shifting" to severe disease, and the corresponding escalation in morbidity and mortality associated with it.

We begin by advancing a number of "Imagine" statements specifically focused upon the marked mitigation of this pandemic and its effects upon people, families, communities and institutions. Further, we then move to a specific, albeit not dogmatic, regimen which addresses a diversity of semiologic factors associated with COVID-19, and which can be remedied with the employment of establish practice principles, and their simple implementation given that all that we proscribe in the way of either devices, techniques, as well as nutritional agents and prescription medications are all generic and widely available throughout the world. This paper is really intended to showcase our protocol in conjunction with medical illustrations to be utilized for purposes of organization, and for counseling each of our individual patients and their families. Similarly, we provide a highly detailed figure along with a table of detailed legends such that the pathophysiologic underpinnings of COVID-19 can be parsed and individually addressed in terms of mitigating or even remission exacting effects of our proposed interventions. This paper is accompanied by a YouTube video that shall be released in synchrony with the publication of this manuscript. The multimedia architecture of the video is intended to inform, educate, counsel, inspire, and to build confidence both among those infected, as well as their family members, and their CARE provider alliances.

It is our hope that by bringing this real-world experience to light, that it shall broadly illuminate for all to see, that part of solving the complex riddle of the SARS-CoV-2 agent and its manifestation as COVID-19, is to step back and take a broader view of the inception of the illness, and to exploit the vast toolbox of established medical, health, and wellness capabilities that can be wielded with predictable effects, including the ability to abort the infection, and thereby abolish the mechanisms responsible for the consequences of the pandemic across the entire spectrum of human endeavor. The reports of new mutations, in conjunction with spikes of the illness being disseminated throughout the world, suggests that this paper, albeit too late for the many who have succumbed to the illness, or who have what appear to be recalcitrant residual deficits, it"s really "about time" that something tangible be offered to mitigate the illness and prevent the transition to severe disease.

Since the inception of COVID-19, we finally can recognize CARE pathways addressing each of the early mechanisms and manifestations of this illness, while assembling a concerted attack directly upon the culprit, as well as the application of a treatment strategy which finally is focused upon the most relevant constellation of treatable facets of this most dangerous, complex, and clever microbial agent.

From the start, we have been endowed all along with the ability to "checkmate" this challenger, even despite it targeting of one of our body"s most vulnerable and lifesustaining circuitries. Even at the most remote reaches of our lung physiology, employment of site-selective inhalational therapies, in conjunction with nutritional support measures, pulmonary hygiene and respiratory muscle training, we can begin to see a path forward by which to return our world to normality, while learning lessons that shall prepare us for future challenges that shall no doubt be forthcoming.

Taking the medical initiative early to confront both the virus and tissue injury mechanisms fomented by it, advances our acumen as Master Clinicians; ones capable of rendering the entire SARS family to the realm of "rookies".

Herein the time is right to now begin by asking you, the reader, to be opened minded enough to consider the "IMAGINE" statements that follow; inspired by John Lennon"s 1971 verse from his raison d'être; "IMAGINE". READ ON…

If the treatment were based on evidenced-based medical principles and such a regimen were completely detailed right here for you, your family, and your healthcare provider.

If, while you are waiting to get vaccinated, those already infected could receive a simple treatment regimen along with education on how to administer it at home, and education on when to contact their medical provider or go to the emergency department.

If this treatment were cheap, involved both over-the-counter therapies, and only a few prescriptions, and was administered over a 10-day course in most patients.

If the vast majority utilizing such a regimen would never advance to severe COVID-19, would NOT require hospitalization, and as such, would completely avoid ventilatory support, and death.

If the effectiveness of this treatment strategy produced similar protective effects across the age, gender, racial, and co-morbid condition demographic spectrum.

diagnosis (pre-emption to avoid progression to severe disease), NOT wait for a favorable prognostic outcome that may never materialize, or until the patient is sufficiently sick to warrant hospitalization (a reactive and much more dangerous strategy). Such delay to act early may be too late to avoid progression to severe COVID-19. Here, we have provided the Imagine That we have provided the details of a protocol assembled by our team of colleagues, and have already observed nearly uniform capability to rescue over 1,000 patients at the time when their infection is early in the course. A time that represents our best chance to mitigate suffering, and more importantly, to prevent progression to severe disease and its associated ramifications, including death. This is especially key when patients experience the perception of "difficulty getting in enough air"" (a symptom likely implicating a reduced negative inspiratory force [NIF]).

Instructions from your care provider should be given as to when to notify them (e.g. with oxygen saturations in the low 90s or a significant change over a defined period). [3] [4] [5] [6] [7] 

Body temperature is a key indicator of both infection as well as ongoing inflammatory mechanisms not being adequately treated (e.g. release of cytokines, especially interleukin-1; IL-1)

Monitor and document temperature twice daily; more frequently if you perceive changes, or instructed by your care provider. If temperature exceeds 100.4˚ (F)/38˚ (C) and/or is rising, you should contact your care provider.

Instructions for use of fever reducers (ibuprofen, acetaminophen/paracetamol, etc.) will vary across countries and even across physicians in the same country. We generally provide instructions for the administration of these agents (dose and frequency) and in response to temperature parameters (e.g. 400-600 mg of ibuprofen daily to twice daily to attempt to lower and maintain a normal body temperature between certain parameters; such as an attempt to maintain body temperature below 100.4 °F/38 o C).

Please assess blood pressure and heart rate lying supine (flat), sitting, and then standing (with 2-minute intervals between each) to assess for orthostatic changes (drop in systolic blood pressure of 10-20 mm Hg, with the corresponding escalation in heart rate, which may be secondary to orthostatic hypotension, often in response to dehydration). 

We recommend 300 mg of Benfotiamine to improve bioenergetics and reduce tissue damage. [13] [14] [15] [16] 

We instruct our patients to take vitamin D 3 at 10,000 units daily, every day, as this vitamin at this dosage produces vital immune-modulating effects that are favorable in several conditions, now including COVID-19. [14] [15] [16] [17] [18] [19] [20] [21] 6. Vitamin C We suggest ingestions of 2 g of Vitamin C crystals daily (ascorbic acid crystals) or tablets/capsules, which provide a variety of benefits, including the reduction of oxidative stress associated with the Prolific Activation of a Network Immune Inflammatory Crisis ("PANIC"). [22] 

Zinc deficiency is associated with worse COVID-19 prognoses, perhaps related to the associated increase in clot formation and stasis in the para-alveolar pulmonary capillary network. Further, Zinc deficiency can contribute to insomnia, compromising sleep hygiene when it is needed most, in addition to diminished smell, taste, and libido, as well as reduced erectile function and orgasm.

Adequate Zinc reduces infection risk, reduces oxidative stress, attenuates the release of inflammatory cytokines, and contributes to the induction and maintenance of sleep. This helps with clotting and immune modulation.

We recommend rMetx zinc-silver solution (ZnAg); a clear liquid solution of the minerals, zinc (Zn) and silver (Ag), present in a deionized purified water suspension as dissolved ions, measured in parts per million (ppm, g/mL). The dose of rMetx is 30 -60 ml Q12 hours as needed. Recommended on an empty stomach and nothing by mouth for 20 min after.

Alternatively, we recommend 10-40 mg of Zinc daily in the form of Zinc gluconate or Zinc picolinate. Avoid overdosing (beyond 50 mg daily), which can reduce copper absorption, leading to myelopathy, nausea, vomiting, tenesmus, diarrhea, and headaches. [23] [24] [25] 

We recommend a course of antibiotics (a "Z-Pak" of azithromycin vs 5 days of amoxicillin/clavulanate b.i.d. vs Bactrim DS b.i.d. for 5 days), as this would address any inspissated, deep pulmonary tree bacterial elements mixed with mucus, which could become a source of further immune stimulation (i.e. PANIC). 

To promote liquification of mucus for subsequent mobilization out of the peripheral bronchopulmonary tree, we recommend using guaifenesin (available over the counter in most countries) twice daily at 1200 mg, extended-release formulation.

If the cough is excessive or fatiguing, then guaifenesin + dextromethorphan (the latter, a cough suppressant, can also attenuate adenosine mediated headaches) is indicated.

Mobilization (expectoration) of distal mucus (in those with no cough, nonproductive cough, and with productive cough) by liquefying (following step 9, above). Follow by either manual postural percussion or use of a percussion vibratory instrument on the back, to dislodge mucus in the upper and lower lobes (right and left), and apply similar percussion to the right middle lobe, also known as the lingular lobe. This is key, as the right middle lobe is the one at greatest risk of consolidation and infection, along with atelectasis (a partial or complete collapse of the lung).

Performance of pulmonary exercises promotes normalizing pulmonary functioning via improved conditioning. 10-20 breaths of inspiration and expiration with The Breather (a respiratory muscle trainer which can be purchased online, as well as other devices such as incentive spirometry device), three times daily. Begin at setting #1; each day see if the patient can advance by one setting until arriving at the top setting (e.g. with the highest resistance to inspiration and expiration). [56] [57] [58] [59] [60] Advance Therapy # 1

Journal Pre-proof Advancing Therapy # 2

Should the patient continue to experience fever and/or other COVID-19 symptoms despite the above regimen, we consider the addition of the oral steroid dexamethasone.

If utilized, take Dexamethasone in the morning each day for 5 days, at a dose of 4-6 mg each day, generally with breakfast. Be mindful of the potential risk of steroid psychosis (euphoria, agitation, confusion, delusional thinking, obsessive

We recommend inhalational L-albuterol to facilitate improved ventilation and delivery of medication to the distal bronchopulmonary tree. L-albuterol has the active "R" isomer of the molecule and serves to relax bronchial smooth muscle, and is more lung selective than the racemic form (R & D isomers).

Albuterol is a beta-2 adrenergic agonist and serves to relax bronchiole smooth muscle. Additionally, via its interaction with beta-receptors on lung mononuclear cells (especially macrophages, T-and B-lymphocytes), it promotes the escalation in intracellular cAMP, and thereby the transition of mononuclear cells from proinflammatory to modulated and even to a regulatory cell phenotype. This mitigates the "Prolific Activation of a Network Immune Inflammatory Crisis" (PANIC), the principal mechanisms of COVID-19 associated with tissue damage of the lungs. [61] [62] [63] [64] [65] We recommend 2 puffs twice daily, along with 2 puffs of a budesonide inhaler (Pulmicort) administered 5 minutes after taking L-albuterol inhaler therapy, to provide some time for bronchial smooth muscle relaxation.

This subsequently acts to coordinate a constellation of steroid-mediated antiinflammatory actions, also serving to mitigate the effects of COVID-19-associated inflammatory activity. After administration of the two inhalational puffs of Lalbuterol, followed by the two puffs of budesonide, we recommend that the patient gargle with water x 2 and spit, to avoid the development of thrush. [66] [67] 

Unless formal anticoagulation is indicated, (per guidelines contingent upon D-Dimer levels), we recommend 1 baby aspirin daily (81 mg) for purposes of reducing clot and sludging via platelet inhibition (unless aspirin in the patient is contraindicated). [68] [69] [70] [71] [72] [73] [74] [75] [76] [77] 

Avoid overhydrating because increased protein-rich fluid can accumulate in the distal bronchopulmonary tree, which can increase the distance between the alveolar epithelium and the pulmonary vascular capillary bed endothelium, thereby compromising the gas exchange apparatus (as demonstrated in the FACCT TRIAL). If your patient is dehydrated (e.g. from diarrhea), then fluid reconstitution and potentially potassium repletion may need to be considered. [78] [79] [80] [81] [82] 

Methotrexate is considered a "necessary" treatment by the World Health Organization (WHO) given its diversity of immune modulatory and anti-inflammatory actions [92] [93] [94] [95] [96] [97] [98] [99] [100] [101] [102] [103] [104] [105] [106] [107] [108] .

1. High-dose oral weekly Methotrexate (15 mg weekly x 2) 2. A folate poor diet (i.e. reduced vegetables, and instead emphasize meat and seafood for the duration of the 10-day regimen) 3. Daily Folate at 2 mg, starting 12 hours after the oral Methotrexate dose administration, to define precise folate intake.

Finally, we recommend that you contact your treating care provider every day during this 10-day course to assess your status.

Several factors influence hospital admission including: 1. Persistent fever 2. Falling oxygen saturation, or not improving despite this regimen 3. Pulmonary fatigue not resolving 4. Evolution of progressive symptoms, such as those suggestive of stroke, heart attack, renal failure, persistent/worsening headache, behavioral change We are still learning about these great additions to the war against COVID-19 and a vaccine alone is only part of the battle. Encourage your family, friends, and coworkers to follow suit by practicing social distancing, hygiene measures, and the use of facial covering (i.e. a mask) until the pandemic is over [109] [110] c) you are outside of your home but others are not around.

Coronavirus can survive on surfaces that we pick up with our hands, potentially transferring the COVID-19 agent to our mucus membranes (and then to the lungs), or to others. Please continue to wash your hands frequently.

The risk of infection and serious consequences remain high even for younger populations. . We must all do our part to protect ourselves, and each other. 

To prevent the organization of complex inspissated mucus with bacterial flora in the distal bronchopulmonary tree, potentially serving to "endocast" the bronchoalveolar anatomy responsible for ventilation and perfusion characteristics germane to high-fidelity gas exchange.

The SARS-CoV-2 virus, which causes COVID-19, principally does so by targeting our most vulnerable lung anatomy, the bronchoalveolar terminals where high-fidelity gas exchange occurs, representing the entire body"s supply of oxyhemoglobin and its delivery via cardiopulmonary physiology [2, 112] .

To maintain such constant and uninterrupted gas exchange, both ventilation and pulmonary arterial perfusion must be commensurate with threshold states that guarantee the reliable delivery of oxygen to the pulmonary arterial capillary network, while the lung parenchyma simultaneously expels carbon dioxide by reverse expiratory flow, oscillating with the inspiration of fresh air whose composition is 21% O 2 . Oxygenated pulmonary venous return to the left heart is then prepared to deliver cardiac output via the left ventricular systolic pump and its ejection fraction of blood in to and out of the aortic root.

The mobilization of dangerous mucus organization in the distal bronchioles is achieved with a combination of:

1. Liquification via 800mg of oral twice daily guaifenesin, 2. Excessive cough, which can be counteracted by the use of guaifenesin with dextromethorphan 3. Manual percussion of the upper and lower lung lobes from the back and anterior percussion of the right middle lobe, which can serve to mobilize and ultimately expectorate the mucus burden in the distal lung fields. 4. Percussion and mucus expectoration, which is more efficiently achieved by utilizing a vibratory "gun," making this part of pulmonary hygiene less cumbersome and exhausting for the assistant, partner, or family member. 5. Special attention given to the right middle lung lobe, approaching anteriorly (between the 4 th -6 th intercostal spaces, with the breast lifted in those with abundant breast tissue.) Remember that the right middle lobe is most predisposed to the development of pneumonic consolidation (i.e. pneumonia and pneumonitis), as well as atelectasis (i.e. lobular collapse and its associated 

Activation of a Network Immune Inflammatory Crisis ("PANIC") results in complex supply/demand challenges to the bioenergetic system, a failure of which contributes to tissue destruction

Benfotiamine is an ultra-purified form of thiamine (vitamin B1), a crucial co-factor across several biochemical enzyme systems that are crucial for meeting the bioenergetic demands of cells. This is particularly challenging to those with highly stringent thresholds, beyond which supply/demand mismatch and can contribute to the failure of many crucial cellular physiologic mechanisms, including a failure in the efficiency of transition from anaerobic glycolytic to aerobic mechanisms of oxidative phosphorylation, which is required for producing the bioenergetic cellular currency (i.e. ATP). High-fidelity gas exchange providing the necessary oxygenation in order to drive the tricarboxylic acid (TCA) cycle, and Benfotiamine, a co-factor for pyruvate dehydrogenase, which along with alpha-lipoic acid and flavin adenine dinucleotide (FAD), catalyzes the incorporation of pyruvate into oxaloacetate, the first step of the TCA cycle.

Aspirin therapy can serve to reduce sludging via platelet inhibition. Depending upon D-Dimer criteria, some patients may require formal anticoagulation.

L-albuterol can promote smooth muscle relaxation, thereby improving ventilation at the bronchoalveolar gas exchange apparatus. Further, this agent acts as an agonist at the beta-2-adrenergic receptor on lung mononuclear cells (e.g. lymphocytes and macrophages) resulting in the escalation of intracellular cAMP, resulting in improved immune regulation and attenuation of a Prolific Activation of a Network-Immune Inflammatory Crisis (PANIC) [2, 116] .

Budesonide is an inhalational steroid that promotes a constellation of anti-inflammatory mechanisms relevant to reducing PANIC and reconstitutes coordinated regulatory influences in the SARS-CoV-2 infected lung.

Vitamins D 3 , C, and Zinc all have favorable effects upon oxidative stress, immune regulation, and influence on clot formation reduction.

symptoms often reflect inadequate control over SARS-CoV-2 mediated COVID and its constellation of triggered inflammatory mechanisms; in essence, PANIC. STEP 1: Administer the potent oral and non-mineralocorticoid steroid, dexamethasone, at 4-6 mg, taken in the morning with breakfast for 5 days (some use longer regimens). This can rapidly attenuate systemic mechanisms of PANIC, such as the elaboration of cytokine storms, most prominently with IL-1, which targets hypothalamic temperature regulatory networks, and IL-6, which can provoke the activation of several injurious inflammatory networks exceeding intra-and inter-network regulatory mechanisms. These mechanisms normally serve to mitigate bystander injury to host tissues wherein such paroxysmal bursts of irrationally exuberant inflammatory crises are fomented. 

There does come a time when the above interventions are not sufficient to avoid the "right-shifting" of the patient from mild/moderate COVID-19 into severe disease. Such circumstances necessitate hospital admission for:

1. Close observation 2. Augmentation of oxygen support (e.g. 1-4 L of O 2 by nasal cannula 3. Expanded investigations to ascertain the severity of metabolic and hematologic derangements (Ferritin, hsCRP, D-Dimer), presence of concomitant infection (including secondary pneumonia, if bacterial suspected prompting treatment with IV antibiotics), and CT assessment of the lung, to stage the severity and burden of injury to the lung parenchyma. Further, cardiac investigations are increasingly being performed given increasing evidence that COVID-19 can affect the heart, predisposing patients to markedly increased morbidity and mortality.

To diagnostically and therapeutically address extra-pulmonary organ pathologies, such as brain imaging to assess for stroke, renal insufficiency or failure, and endocrine and neuroendocrine pathology. 

While much has been learned over the past year about the COVID-19 pandemic and the SARS-CoV-2 Coronavirus which causes it, we are increasingly recognizing that while the lung is the principal target of the disease, virtually any tissue or body organ can ultimately become a target of the disease process (either via direct viral targeting, or through secondary mechanisms whereby damage is produced by a compromise in the necessary, constant, and high fidelity delivery of life-sustaining oxygen-rich blood everywhere throughout the body.

A crucial area of scientific inquiry shall address the rapidly expanding observation that subsequent to surviving COVID-19; even those with the mildest variants of this disorder, can be predisposed to the development of a post-COVID-19 syndrome; so-called "Long-Hauler"s" syndrome [112] [113] [114] [115] .

Long-Hauler"s syndrome is characterized by a constellation of recalcitrant symptoms, which can include chronic fatigue, alterations in cognitive capabilities, persistent breathing problems, exercise intolerance, as well as residual deficits in those who have suffered stroke, seizures, heart attack, kidney and liver derangements, as well as disturbances in the gastrointestinal tract [112] [113] [114] [115] .

We believe that the information underscored above, further support our contention about the role of early treatment intervention, as both a prevention and disease attenuation strategy. "Time is tissue", and the earlier we can intervene to quench the exaggerated immune network inflammatory responses to the SARS-CoV-2 agent, the less likely our patients are to progressively advance to severe disease, and thereby manifest more severe morbidity, persistence of post-COVID-19 syndromes, and even death from this very serious infection [116] .

A Collaborative Multidisciplinary Approach to the Management of Coronavirus Disease 2019 in the Hospital Setting

SARS-CoV-2 triggered 'PANIC' attack in severe COVID-19

A Novel Large Scale Integrated Telemonitoring Program for COVID-19

Ambulatory COVID Study Team. The Clinical Course of COVID-19 in the Outpatient Setting: A Prospective Cohort Study. Open Forum Infect Dis

Smartphone Biosensor With App Meets FDA/ISO Standards for Clinical

Treat Mild/Moderate COVID-19: Prevent Severe Disease Frohman 34

Pulse Oximetry and Can Be Reliably Used by a Wide Range of Patients

Accuracy of Samsung Smartphone Integrated Pulse Oximetry Meets Full FDA Clearance Standards for Clinical Use

Consumer-grade Pulse Oximeters are Accurate for Home and Medical Use: Implications for their Use

Epub ahead of print

Covid-19 and Disparities in Nutrition and Obesity

Perspective: Nutritional Strategies Targeting the Gut Microbiome to Mitigate COVID-19 Outcomes

The 13

Protective effects of benfotiamine on irisin activity in methotrexate-induced liver injury in rats

Therapeutic Prospects for Th-17 Cell Immune Storm Syndrome and Neurological Symptoms in COVID-19: Thiamine Efficacy and Safety, In-vitro Evidence and Pharmacokinetic Profile. medRxiv

MATH+ protocol for the treatment of SARS-CoV-2 infection: the scientific rationale

Treat Mild/Moderate COVID-19: Prevent Severe Disease Frohman 36

Rationale for the "MATH+" Hospital Treatment Protocol for COVID-19

Putative roles of vitamin D in modulating immune response and immunopathology associated with COVID-19

The History of Methylprednisolone, Ascorbic Acid, Thiamine, and Heparin Protocol and I-MASK+ Ivermectin Protocol for COVID-19

Vitamin D and Lung Outcomes in Elderly COVID-19 Patients

Vitamin D and disease severity in coronavirus disease 19 (COVID-19). Reumatismo

Association of vitamin D status with hospital morbidity and mortality in adult

Treat Mild/Moderate COVID-19: Prevent Severe Disease Frohman 37

COVID-19 patients

Epub ahead of print

Impact of vitamins A, B, C, D, and E supplementation on improvement and mortality rate in ICU patients with coronavirus-19: a structured summary of a study protocol for a randomized controlled trial

COVID-19: Poor outcomes in patients with zinc deficiency

Three novel prevention, diagnostic, and treatment options for COVID-19 urgently necessitating controlled randomized trials. Med Hypotheses

Cytokine Storm and Mucus Hypersecretion in COVID-19: Review of Mechanisms

Initial assessment and management of respiratory infections in persons with spinal cord injuries and disorders in the COVID-19 era

Defensive Properties of Mucin Glycoproteins during Respiratory Infections-Relevance for SARS-CoV-2. mBio

Distinct phenotypes require distinct respiratory management strategies in severe COVID-19

Protective potential of expectorants against COVID-19. Med Hypotheses

Effects of guaifenesin, N-acetylcysteine, and ambroxol on MUC5AC and mucociliary transport in primary differentiated human tracheal-bronchial cells

Integrative medicine considerations for convalescence from mild-to-moderate COVID-19 disease. Explore (NY)

A case for inspiratory muscle training in SCI: potential role as a preventative tool in infectious respiratory diseases like COVID-19. Spinal Cord Ser Cases

Effect of respiratory rehabilitation training on elderly patients with COVID-19: A protocol for systematic review and meta-analysis. Medicine (Baltimore)

Safety and Efficacy of Chest Physiotherapy in Patients With COVID-19: A Critical Review

Physical Medicine and Rehabilitation and Pulmonary Rehabilitation for COVID-19

Treat Mild/Moderate COVID-19: Prevent Severe Disease Frohman 45

Physical Therapist Management of COVID-19 in the Intensive Care Unit: The West China Hospital Experience

A randomized controlled double-masked trial of albuterol add-on therapy in patients with multiple sclerosis

Oral salbutamol decreases IL-12 in patients with secondary progressive multiple sclerosis

Epub 2001/06/30

Potential of beta2-adrenoceptor agonists as add-on therapy for multiple sclerosis: focus on salbutamol (albuterol)

Beta2-adrenergic agonist use and the risk of multiple sclerosis: a total population-based case-control study

Why asthma might surprisingly protect against poor outcomes in COVID-19

Clinical outcomes after early ambulatory multidrug therapy for high-risk SARS-CoV-2 (COVID-19) infection

Inhibitory effects of glycopyrronium, formoterol, and budesonide on coronavirus HCoV-229E replication and cytokine production by primary cultures of human nasal and tracheal epithelial cells. Respir Investig

The use of aspirin for primary prevention of cardiovascular disease is associated with a lower likelihood of COVID-19 infection

Old drug, new Trick? The rationale for the treatment of COVID-19 with activated protein C. Med Hypotheses

Platelet and Endothelial Activation as Potential Mechanisms Behind the Thrombotic Complications of COVID-19 Patients

Effect of lowdose aspirin on mortality and viral duration of the hospitalized adults with COVID-19. Medicine (Baltimore)

Oral corticoid, aspirin, anticoagulant, colchicine, and furosemide to improve the outcome of hospitalized COVID-19 patients -the COCAA-COLA cohort study

Treat Mild/Moderate COVID-19: Prevent Severe Disease Frohman 48

Association of mortality and aspirin prescription for COVID-19 patients at the Veterans Health Administration

A Rare Case of Acute Pericarditis Due to SARS-CoV-2 Managed With Aspirin and Colchicine

Intermediate-dose anticoagulation, aspirin, and in-hospital mortality in COVID-19: a propensity score-matched analysis. medRxiv

Aspirin in COVID-19 related ARDS: an old, low-cost therapy with a strong rationale

National Heart Lung and Blood Institute Acute Respiratory Distress Syndrome Clinical Trials Network. Fluid management with a simplified conservative protocol for the

Treat Mild/Moderate COVID-19: Prevent Severe Disease Frohman 49

acute respiratory distress syndrome*

National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome Network. Fluid balance, diuretic use, and mortality in acute kidney injury

National Institutes of Health/National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome Clinical Trials Network. Less is more: improved outcomes in surgical patients with conservative fluid administration and central venous catheter monitoring

A perspective on the fluids and catheters treatment trial (FACTT)

Effect of airway pressure display on interobserver agreement in the assessment of vascular pressures in patients with acute lung injury and acute respiratory distress syndrome

Adjunctive Therapy for Refractory Hypoxemia in Non-Intubated Patients with COVID-19 Acute Respiratory Failure: Guidance from an International Group of Healthcare Workers

Effect of proning in patients with COVID-19 acute hypoxemic respiratory failure receiving noninvasive oxygen therapy

Role of awake prone positioning in patients with moderate-to-severe COVID-19: an experience from a developing country. Monaldi Arch Chest Dis

A Case-Control Study of Prone Positioning in Awake and Nonintubated Hospitalized Coronavirus

Treat Mild/Moderate COVID-19: Prevent Severe Disease Frohman 51

Crit Care Explor

Study of the Treatment and Outcomes in Critically Ill Patients with Coronavirus Disease (STOP-COVID) Investigators. Prone Positioning and Survival in Mechanically Ventilated Patients With Coronavirus Disease

Epub ahead of print

The effect of the timing of dexamethasone administration in patients with COVID-19 pneumonia. Tuberc Respir Dis (Seoul)

Single-Arm, Open-Label Phase 2 Trial of Preemptive Methylprednisolone to Avert Progression to Respiratory Failure in High-Risk Patients with COVID-19. medRxiv

Therapeutic role of corticosteroids in COVID-19: a systematic review of registered clinical trials

Treat Mild/Moderate COVID-19: Prevent Severe Disease Frohman 52

A review on function and side effects of systemic corticosteroids used in high-grade COVID-19 to prevent cytokine storms

Methotrexate inhibits SARS-CoV-2 virus replication "in vitro

Rational administration schedule for high-dose methotrexate in patients with primary central nervous system lymphoma

Risk of liver disease in methotrexate treated patients

Methotrexate an old drug with new tricks

Treat Mild/Moderate COVID-19: Prevent Severe Disease Frohman 53

Mechanism of action of methotrexate in rheumatoid arthritis, and the search for biomarkers

The antiinflammatory mechanism of methotrexate depends on extracellular conversion of adenine nucleotides to adenosine by ecto-5′-nucleotidase:findings in a study of ecto-5′-nucleotidase gene-deficient mice

Methotrexate is a JAK/STAT pathway inhibitor

Endothelial dihydrofolate reductase: critical for nitric oxide bioavailability and role in angiotensin II uncoupling of endothelial nitric oxide synthase

Low dose methotrexate induces apoptosis with reactive oxygen species involvement in T lymphocytic cell lines to a greater extent than in monocytic lines

The anti-inflammatory actions of methotrexate are critically dependent upon the production of reactive oxygen species

Methotrexate suppresses the interleukin-6 induced generation of reactive oxygen species in the synoviocytes of rheumatoid arthritis

High-mobility group box 1 (HMGB1) as a master regulator of innate immunity

HMGB1: endogenous danger signaling

Release of chromatin protein HMGB1 by necrotic cells triggers inflammation

Advanced glycation end product receptor-mediated cellular dysfunction

Treat Mild/Moderate COVID-19: Prevent Severe Disease Frohman 55

The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses

High-dose methotrexate with leucovorin rescue: for monumentally severe CNS inflammatory syndromes

Survival of SARS-CoV-2 and influenza virus on the human skin: Importance of hand hygiene in COVID-19

Breathing Is Enough: For the Spread of Influenza Virus and SARS-CoV-2 by Breathing Only

Correlation of autopsy pathological findings and imaging features from 9 fatal cases of COVID-19 pneumonia. Medicine (Baltimore)

Treat Mild/Moderate COVID-19: Prevent Severe Disease Frohman 56

Potential Application of Whole Body Vibration Exercise For Improving The Clinical Conditions of COVID-19 Infected Individuals:A Narrative Review From the World Association of Vibration Exercise Experts (WAVex) Panel

Historical Insight into Infections and Disorders Associated with Neurological and Psychiatric Sequelae Similar to Long COVID

Deleterious Outcomes in Long-Hauler COVID-19: The Effects of SARS-CoV-2 on the CNS in Chronic COVID Syndrome

Potential Application of Whole Body Vibration Exercise For Improving The Clinical Conditions of